U.S. researchers began an early stage clinical trial of a vaccine to prevent genital herpes disease by removing two key proteins so the virus cannot multiply. The vaccine was developed by David Knipe, Higgins Professor of Microbiology and Immunobiology and chair of the Harvard Program in Virology at HMS.
News & Research
